title: Effects of hyperactivity of the maternal hypothalamic-pituitary-adrenal (HPA) axis during pregnancy on the development of the HPA axis and brain monoamines of the offspring.
abstract: Offspring of mothers with adrenal hyperactivity during pregnancy have been reported to have changes in brain monoamines and altered emotional, reactive, sexual and maternal behavior. Since the hypothalamic-pituitary-adrenal (HPA) axis is known to be involved in the expression of such behaviors and is itself under monoaminergic control, we examined the development of the HPA axis and brain monoamines in pups whose mothers had adrenal hyperactivity, reflecting administration of ACTH during the last third of their pregnancy. The adrenals of the experimental animals weighed less and had aberrant morphology. The abnormal histology was more pronounced in the adrenals of the experimental females than of the males, suggesting that females were more vulnerable to the prenatal treatment. In both experimental males and females, basal plasma corticosterone levels were higher compared to the controls, while after exposure to stress, experimental animals attained lower plasma corticosterone levels than the controls. In the brain of the experimental animals, dopaminergic activity appeared to be decreased, while serotonergic activity increased. Our results indicate that the prenatal treatment affected brain development in the offspring and as a consequence programmed the developing HPA axis in such a way as to hyperfunction under basal conditions, leading to its exhaustion and its inability to react properly to stress.
authors.affiliation: Laboratory of Histology-Embryology, Athens University Medical School, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Fameli
authors.forename: E
authors.initials: E
authors.lastname: Kitraki
authors.forename: F
authors.initials: F
authors.lastname: Stylianopoulou
mesh_terms: D000311:Adrenal Glands / Q000033:anatomy & histology / Q000254:growth & development; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001923:Brain Chemistry / Q000502:physiology*; D003345:Corticosterone / Q000097:blood; D005260:Female; D007030:Hypothalamo-Hypophyseal System / Q000254:growth & development* / Q000502:physiology*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010913:Pituitary-Adrenal System / Q000254:growth & development* / Q000502:physiology*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000502:physiology*; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D013315:Stress, Psychological / Q000378:metabolism
chemical_list: D015306:Biogenic Monoamines; D011965:Receptors, Glucocorticoid; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone